{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2-targeted+Therapy&page=4",
    "query": {
      "intervention": "HER2-targeted Therapy",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 110,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2-targeted+Therapy&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HER2-targeted+Therapy&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T23:42:18.574Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03219476",
      "title": "Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Invasive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 37,
      "start_date": "2017-02-05",
      "completion_date": "2025-03-20",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219476"
    },
    {
      "nct_id": "NCT04132817",
      "title": "A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-09-22",
      "completion_date": "2022-08-15",
      "has_results": false,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04132817"
    },
    {
      "nct_id": "NCT05559164",
      "title": "Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiac Toxicity",
        "Early-stage Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Lipitor 40mg Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2022-09-19",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 10,
      "location_summary": "Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 5 more",
      "locations": [
        {
          "city": "Elizabeth",
          "state": "New Jersey"
        },
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "Jersey City",
          "state": "New Jersey"
        },
        {
          "city": "Lakewood",
          "state": "New Jersey"
        },
        {
          "city": "Long Branch",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05559164"
    },
    {
      "nct_id": "NCT07459673",
      "title": "HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "HER2-positive Breast Cancer",
        "Breast Cancer Stage IV"
      ],
      "interventions": [
        {
          "name": "Personalis NeXT Personal",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Natera Signatera",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "fam-trastuzumab deruxtecan-nxki (T-DXd)",
          "type": "DRUG"
        },
        {
          "name": "pertuzumab, called T-DXd+P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-03-04",
      "completion_date": "2030-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07459673"
    },
    {
      "nct_id": "NCT03970382",
      "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "NeoTCR-P1 adoptive cell therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PACT Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-07-03",
      "completion_date": "2022-08-12",
      "has_results": false,
      "last_update_posted_date": "2022-08-18",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970382"
    },
    {
      "nct_id": "NCT04602117",
      "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2 Low",
        "SYD-985",
        "SYD985",
        "Vic-trastuzumab Duocarmazine",
        "Metastatic Cancer",
        "Metastatic Breast Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic",
        "HER2 Low Breast Cancer",
        "GastroEsophageal Cancer",
        "Gastroesophageal Adenocarcinoma",
        "Endometrium Tumor",
        "Ovarian Cancer",
        "Ovarian Carcinoma",
        "HER2-positive Gastric Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER-2 Protein Overexpression",
        "HER2 Low HR Positive",
        "HR Positive",
        "Hormone Receptor-positive Breast Cancer",
        "Estrogen Receptor Positive Tumor",
        "Progesterone Receptor-positive Breast Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Negative Breast Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QuantumLeap Healthcare Collaborative",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-07-28",
      "completion_date": "2021-11-17",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04602117"
    },
    {
      "nct_id": "NCT03587740",
      "title": "ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "T-DM1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2018-08-22",
      "completion_date": "2027-08-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Stamford, Connecticut • Boston, Massachusetts + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Brighton",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03587740"
    },
    {
      "nct_id": "NCT06072612",
      "title": "Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Breast Neoplasm",
        "Breast Cancer Metastatic",
        "End Stage Cancer"
      ],
      "interventions": [
        {
          "name": "SV-BR-1-GM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Interferon infiltration of the inoculation site",
          "type": "DRUG"
        },
        {
          "name": "Retifanlimab",
          "type": "DRUG"
        },
        {
          "name": "Treatment of Physician's Choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "BriaCell Therapeutics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 404,
      "start_date": "2023-12-05",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 79,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06072612"
    },
    {
      "nct_id": "NCT06927895",
      "title": "Breast Cancer Implementation Science Study With Educational Intervention",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Educational Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-07-03",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06927895"
    },
    {
      "nct_id": "NCT02605915",
      "title": "Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-Positive Metastatic Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Locally Advanced or Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2015-12-31",
      "completion_date": "2019-11-13",
      "has_results": false,
      "last_update_posted_date": "2020-02-05",
      "last_synced_at": "2026-10-13T23:42:18.574Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Joliet",
          "state": "Illinois"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605915"
    }
  ]
}